Provista Diagnostics (PDx) Announces the Closing of Additional $2.5 Million Series A Preferred Financing  
9/18/2012 9:44:46 AM

Scottsdale, Arizona, Sept. 18, 2012 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc., a provider of oncology-based diagnostic tests and clinical laboratory services to the pharmaceutical and biotechnology industries, today announced that it has sold an additional $2.5 million of Series A preferred stock to qualified institutional and individual investors. This closing brings the total amount raised in the offering to $7.5 million; $5.0 million of Series A preferred stock was previously sold in February and March. Participation in this latest round of funding was offered exclusively to existing shareholders of the company.